Agios Pharmaceuticals
AGIO
238 hedge funds and large institutions have $2.45B invested in Agios Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 97 increasing their positions, 65 reducing their positions, and 32 closing their positions.
494% more call options, than puts
Call options by funds: $128M | Put options by funds: $21.6M
49% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 65
22% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 32
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
16% more capital invested
Capital invested by funds: $2.12B → $2.45B (+$332M)
3.33% more ownership
Funds ownership: 107.65% → 110.99% (+3.3%)
2% more funds holding
Funds holding: 234 → 238 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$34.8M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$25.9M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$24.2M |
| 4 |
BlackRock
New York
|
+$21.3M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$50.4M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$44.2M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$42.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.8M |
| 5 |
EAM
Erste Asset Management
Vienna,
Austria
|
-$16.7M |
AGIO Hedge Fund Activity: Q2 2026 in Review
238 of the 8,299 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2026, worth a combined $2.45B — up 16% from $2.12B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new AGIO positions and 32 closed out — a net gain of 7 holders — while 97 added to existing stakes and 65 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $34.8M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $50.4M sold.
- 238 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2026, up from 234 in Q1 2026.
- Funds reported $2.45B of Agios Pharmaceuticals stock for Q2 2026, up 16% quarter-over-quarter.
- 39 funds opened new Agios Pharmaceuticals positions in Q2 2026 and 32 closed out, a net change of +7 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2026 was ADAR1 Capital Management, an estimated $34.8M added.
- The largest Agios Pharmaceuticals seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $50.4M sold.
Based on aggregated 13F filings for Q2 2026.